Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
Aimery de Gramont(Institut Hospitalier Franco Britannique), Paulo M. Hoff(Apple (Israel)), G. Bodoky(Unified Szent István and Szent László Hospital), Ramón Salazar(Leiden University Medical Center), Martina Makrutzki(Roche (Switzerland)), David Cunningham(Royal Marsden NHS Foundation Trust), Seock‐Ah Im(Seoul National University Hospital), Emilio Bajetta(Fondazione Lanza), Thomas H. Cartwright(College of Central Florida), Stephen Clarke(The University of Sydney), Einat Shacham‐Shmueli(Sheba Medical Center), Thierry André(Sorbonne Université), Fernando Rivera(Marqués de Valdecilla University Hospital), Aijing Shang(Deventer Ziekenhuis), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Malcolm J. Moore(University Health Network), J. Randolph Hecht(Ontario Institute for Cancer Research), Josep Tabernero(Universitat de Vic - Universitat Central de Catalunya)
Cited by 526
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k